Fig. 6

Targeting stroma promoted anti-tumor immunity. A The radar plot showed the correlation between SIPS and the immunogram developed by Bagaev et al. [12] to explore the cancer-immunity interactions in TCGA-OV cohort. B The dot plot showed the PDGFB–PDGFRB signaling among the tumor microenvironmental components in GSE165897 dataset. C The boxplot showed the expression levels of IL6 and TGFB1/2 in CAFs following 24 h-treatment of PDGFB and Sunitinib. D The boxplot showed the PDGFB expression levels in SKOV3, TOV21G, OVCAR5, and ID8 cells following 24 h-treatment of TGFB1. E The boxplot showed the PDGFB expression level in SKOV3, TOV21G, OVCAR5, and ID8 cells following 24 h-treatment of IL6. F The boxplot showed the expression levels of the immune checkpoint molecules IDO1, PD-L1, B7H4, and B7H3 in OVCAR5 cells following 24 h-treatment of the PDGFRB inhibitors Crenolanib and Imatinib. The G boxplot and H pseudo color plot showed the percentage of cleaved caspase-3 positive cells in Trp53^−/−Brca2^−/−-ID8 cells. The cells were pre-treated by PDGFRB inhibitor Sunitinib, followed by co-culturing with activated OT-1 T cells for 3 h. I The circle plot showed the enriched GO biological processes following Niraparib treatment in GSE164088 dataset. J Bioluminescence of C57BL/6j mice after inoculation of Trp53^−/−Brca2^−/−-ID8-luc cells